Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT06300528
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pemigatinib — DRUG
    Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.

Study Details

The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Key Dates

Start date
Oct 3, 2025
Status verified
Nov 2025
Primary completion
Jan 31, 2027
Completion
Dec 31, 2030

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: All Patients
    The study will investigate the effectiveness of pemigatinib.

Primary Outcome Measure

Overall Response Rate (ORR) at Cycle 7 per IWG Response Criteria in subjects with R/R MCL. [ Time Frame: 8 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer Institute at University of UtahSalt Lake CityUtah84112
Rachel Kingsford
[email protected]
801-585-0115

Find similar trials in Salt Lake City, UT

By research site
Huntsman Cancer Institute at University of Utah· Salt Lake City, UT

Related Studies